Patent application number | Description | Published |
20090035343 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 02-05-2009 |
20100021522 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER PEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 01-28-2010 |
20100022450 | OCTREOTIDE IMPLANT HAVING A RELEASE AGENT - Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject. | 01-28-2010 |
20100247594 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 09-30-2010 |
20100292144 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER PEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 11-18-2010 |
20110009338 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 01-13-2011 |
20110206745 | OCTREOTIDE IMPLANT HAVING A RELEASE AGENT - Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject. | 08-25-2011 |
20130115264 | IMPLANTABLE RASAGILINE COMPOSITIONS AND METHODS OF TREATMENT THEREOF - A method of treating the symptoms of Parkinson's disease comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of rasagiline to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes rasagiline hemitartrate and optionally, a sorption enhancer. | 05-09-2013 |
20130252894 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER POLYPEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 09-26-2013 |